Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems

Clinical Pharmacokinetics

Volumn 31, Issue 1, 1996, Pages 65-80

  Schneider, Nina G ^a,d   Lunell, Erik ^b   Olmstead, Richard E ^c   Fagerström, Karl Olov ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Pharmacia & Upjohn AB   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE GUM;

AEROSOL; AREA UNDER THE CURVE; CIGARETTE SMOKING; CLINICAL TRIAL; COUGHING; DRUG ABSORPTION; DRUG ABUSE PATTERN; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG FORMULATION; DRUG SELF ADMINISTRATION; GEL; HEART RATE; HUMAN; INTRANASAL DRUG ADMINISTRATION; NOSE IRRITATION; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; RHINITIS; SNEEZING; THROAT DISEASE; WITHDRAWAL SYNDROME;

EID: 0029949725     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631010-00005     Document Type: Review

References (63)

1. Johnston LM. Tobacco smoking and nicotine. Lancet 1942; II: 742
2. Jarvik ME. The role of nicotine in the smoking habit. In: Hunt WA, editor. Learning mechanisms in smoking. Chicago: Aldine Publishing Co., 1970: 155-90
3. Russell MAH, Feyerabend C. Cigarette smoking: a dependence on high-nicotine boli. Drug Metab Rev 1978; 8(1): 29-57
4. U.S. Department of Health and Human Service. The health consequences of smoking: nicotine addiction. Washington (DC): Government Printing Office, 1988
5. Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict 1991; 86: 1601-6
6. Henningfield JE, Keenan RM. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol 1993; 61 (5): 743-50
7. Jaffe JH. Drug addiction and drug abuse. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. New York: Pergamon, 1990: 522-73
8. Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am 1992; 76: 415-38
9. Ferno O, Lichtneckert SJA, Lundgren CEG. A substitute for tobacco smoking. Psychopharmacologia (Berl) 1973; 31: 201-4
10. Jarvik ME, Schneider NG. Nicotine. In: Lowinson JH, Ruiz P, Millman RB, editors. Comprehensive textbook on substance abuse. 2nd ed. New York: Williams & Wilkins, 1992: 334-56
11. Tang JL, Law M, Wald N. How effective is nicotine replacement therapy in helping people to stop smoking? BMJ 1994; 308 (6920): 21-6
12. Benowitz NL. Nicotine replacement therapy: what has been accomplished: can we do better? Drugs 1993; 45: 157-70
13. Sutherland G, Stapleton JA, Russell MAH, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340: 324-9
14. Hjalmarson A, Franzon M, Westin A, et al. Effect of nicotine nasal spray on smoking cessation: a randomized, placebo-controlled, double-blind study. Arch Intern Med 1994; 154: 2567-72
15. Schneider NG, Olmstead R, Mody F, et al. Efficacy of a nasal nicotine spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995; 90: 1671-82
16. Hardman JGG, Gilman AG, Limbird LL, editors. Goodman and Gilman's pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1995
17. Benowitz NL, Porchet H, Jacob P III. Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res 1989; 79: 279-87
18. Russell MAH, Jarvis MJ, Sutherland G, et al. Nicotine replacement in smoking cessation: absorption of nicotine vapor from smoke-tree cigarettes. JAMA 1987; 257 (23): 3262-5
19. Benowitz NL, Porchet H, Sheiner L, et al. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 1988; 44: 23-8
20. Henningfield JE, London ED, Benowitz NL. Arterial-venous differences in plasma concentrations of nicotine after cigarette smoking. JAMA 1990; 263 (15): 2049-50
21. Russell MAH. Nicotine intake and its regulation. J Psychosom Res 1980; 24: 253-64
22. Rand MJ. Neuropharmacological effect of nicotine in relation to cholinergic mechanisms. In: Nordberg A, Fuxe K, Holmstedt B, et al., editors. Nicotinic receptors in the CNS: their role in synaptic transmission. Oxford: Elsevier, 1989: 3-11
23. Russell MAH, Jarvis MJ, Feyerabend C. Nasal nicotine solution: a potential aid to giving up smoking? BMJ 1983; 286: 683-4
24. Johansson CJ, Olsson P, Bende M, et al. Absolute bioavailability of nicotine applied to different nasal regions. Eur J Clin Pharmacol 1991; 41: 585-8
25. Sutherland G, Russell MAH, Stapleton J, et al. Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology 1992; 108: 512-8
26. Lunell E, Molander L, Andersson M. Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and with topical decongestant. Eur J Clin Pharmacol 1995; 57 (3): 71-5
27. West RJ, Jarvis MJ, Russell MAH, et al. Plasma nicotine concentrations from repeated doses of nasal nicotine solution. Br J Addict 1984; 79: 443-5
28. Lunell E, Molander L. Unpublished data on file. Pharmacia & Upjohn: Helsingborg, Sweden
29. Russell MAH, Jarvis MJ, Feyerabend C. A new age for snuff? Lancet 1980; I (8166): 474-5
30. Russell MAH, Feyerabend C, Cole PV. Plasma nicotine levels after cigarette smoking and chewing nicotine gum. BMJ 1976; I: 1043-6
31. Jarvis MJ, Hajek P, Russell MAH, et al. Nasal nicotine solution as an aid to cigarette withdrawal: a pilot clinical trial. Br J Addict 1987; 82: 983-8
32. Jarvis M. Nasal nicotine solution: its potential in smoking cessation and as a research tool. In: Ockene JK, editor. Pharmacologic treatment of tobacco dependence. Proceedings of the world congress. Cambridge: Harvard Institute for the Study of Smoking Behavior and Policy, 1986: 167-73
33. Perkins KA, Epstein LH, Stiller R, et al. An aerosol spray alternative to cigarette smoking in the study of the behavioral and physiological effects of nicotine. Behav Res Methods Instr Comput 1986; 18: 420-6
34. Pomerleau OF, Flessland KA, Pomerleau CS, et al. Controlled dosing of nicotine via an intranasal nicotine aerosol delivery device (INADD). Psychopharmacology 1992; 108 (4): 519-26
35. Perkins KA, Epstein LH, Stiller R, et al. Chronic and acute tolerance to the heart rate effects of nicotine. Psychopharmacology 1989; 97: 529-34
36. Perkins KA, Sexton JE, Reynolds WA, et al. Comparison of acute subjective and heart rate effects of nicotine intake via tobacco smoking versus nasal spray. Pharmacol Biochem Behav 1994; 47: 295-9
37. Perkins KA, Sexton JE, Stiller RL, et al. Subjective and cardiovascular responses to nicotine combined with caffeine during rest and casual activity. Psychopharmacology 1994; 113: 438-44
38. Pomerleau OF, Hariharan M, Pomerleau CS, et al. Differences between smokers and never-smokers in sensitivity to nicotine: a preliminary report. Addiction 1993; 88: 113-8
39. Perkins KA, Grobe JE, Mitchell SL, et al. Acute tolerance to nicotine in smokers: lack of dissipation within 2 hours. Psychopharmacology 1995; 118 (2): 164-70
40. Benowitz NL, Jacob P, Jones RT, et al. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 1982; 221: 368-72
41. Benowitz NL. Pharmacology of nicotine: tolerance and kinetics. In: Henningfield JE, Stitzer ML, editors. New developments in nicotine-delivery systems. Proceedings of a conference; 1940 Sep 24: Johns Hopkins University, Baltimore (MD), Ossining (NY): Cortlandt Communications, 1991: 11-22
42. Raw M, Jarvis MJ, Feyerabend C, et al. Comparison of nicotine chewing gum and psychological treatments for dependent smokers. BMJ 1980; 281: 481-2
43. McNabb ME. Chewing nicotine gum for 3 months: what happens to plasma nicotine levels? Can Med Assoc J 1984; 131: 589-92
44. Tonnesen P, Fryd V, Hansen M, et al. Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. Addict Behav 1988; 13(1): 17-27
45. Fagerström KO. Efficacy of nicotine chewing gum: a review. In: Pomerleau OF, Pomerleau CS, editors. Nicoline replacement: a critical evaluation. New York: Alan R. Liss, 1988: 109-28
46. Gorsline J. Nicotine pharmacokinetics of four nicoline transdermal systems. Health Values 1993; 17 (2): 20-4
47. Palmer KJ, Buckley MM, Faulds D. Trandermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44 (3): 498-529
48. Leischow SJ. The nicoline vaporizer. Health Values 1994; 18 (3): 4-9
49. Schneider NG, Olmstead R, Nilsson F, et al. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction. In press
50. Benowitz NL, Jacob P, Savanapridi C. Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther 1987; 41: 467-73
51. Johansson CJ. Unpublished data on file. Pharmacia & Upjohn: Helsingborg, Sweden
52. Russell MAH, Jarvis MJ, Devitt G, et al. Nicoline intake by snuff users. BMJ 1981; 283 (6366): 814-7
53. Gourlay SG, Benowitz NL. Arterio-venous differences in plasma nicotine concentrations with nicoline nasal spray [abstract]. Society for Research on Nicoline and Tobacco. Second Annual Scientific Conference: 1996 Mar 15-17; Washington (DC)
54. Sutherland G, Stapleton JA. Nasal nicotine spray for dependent smokers. J Smoking Relat Dis 1994; 5 Suppl. 1: 195-201
55. de Wit H, Bodker B, Ambre J. Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacology 1992; 107: 352-8
56. Hughes JR. Dependence potential and abuse liability of nicotine replacement therapies. Biomed Pharmacother 1989; 43: 11-7
57. Henningfield JE, Jenkins AJ, Steinberg K, et al. The role of nicotine delivery rate in development of selectively targeted medications [abstract]. In: Harris LS. editor. Problems of drug dependence. Proceedings of the 56th Annual Scientific Meeting. The College on Problems of Drug Dependence. Inc.: 1994 Jun 18-23; Vol. II: NIDA research monograph 153: publication #95-3883. Baltimore (MD): USDHHS, 1995: 193
58. Rose JE. The role of upper airway stimulation in smoking. In: Pomerleau OF, Pomerleau CS, editors. Nicotine replacement: a critical evaluation. New York: Alan R. Liss, 1988: 95-106
59. Schneider NG. How to use nicotine gum and other strategies to quit smoking. New York: Simon & Schuster, 1988
60. Schuh KJ, Stitzer ML, Schuh LM, et al. Nicotine nasal spray: abuse liability determination [abstract]. Inaugural Scientific Conference of the Society for Research on Nicotine and Tobacco; 1995 March 24-25; San Diego.
61. Jarvik ME. Beneficial effects of nicotine. Br J Addict 1991; 86: 571-5
62. Fagerström KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology 1993; 111: 271-7
63. Schneider NG. Nicotine therapy in smoking cessation: pharmacokinetic considerations. Clin Pharmacokinet 1992; 23: 169-72